Healthcare Regulation
Medicare biosimilar delays would need proof of launch readiness
CMS wants manufacturers to show a biosimilar is likely to reach the market and that they are ready to launch it before Medicare gives a reference drug more time. If the delay is granted and the biosimilar never arrives, the agency would have a rebate backstop.
CMS is tightening the path manufacturers can use to postpone Medicare drug negotiation over a reference product. The proposal turns biosimilar delay requests into a proof exercise, not a promise, and adds a financial consequence if the expected launch never happens.
- CMS would require evidence that a biosimilar is actually likely to launch.
- Manufacturers would have to show patents probably won't block entry.
- If the delay is granted and the biosimilar never launches, a rebate could be owed.
- The rule lives inside Medicare's drug negotiation program, not a broader pricing overhaul.
- For Medicare beneficiaries, the clock on a lower-cost biosimilar, a biologic copy approved by the Food and Drug Administration, can matter almost as much as the drug itself
For Medicare beneficiaries, the clock on a lower-cost biosimilar, a biologic copy approved by the Food and Drug Administration, can matter almost as much as the drug itself. CMS is proposing to make it harder for manufacturers to win extra time before a reference drug enters Medicare’s negotiation process, and to add a financial backstop if the promised biosimilar never reaches the market.
Under the federal proposal, a company asking for a biosimilar delay would have to show clear and convincing evidence that the copy will be marketed before the high-likelihood deadline. It would also have to show that patents are unlikely to block the launch and that the manufacturer is operationally ready to bring the product to market.
A delay only if the launch looks real
Section 1192(f) gives manufacturers two chances to seek more time, an initial delay and an additional delay. CMS is not changing that basic structure. It is changing the burden attached to it.
The agency wants the request itself to do more than sketch out a future possibility. It would need to demonstrate that the biosimilar is likely to be on shelves, or at least in the market, by the deadline that matters for Medicare pricing. That is meant to separate genuine launch plans from requests built on hope, delay and legal uncertainty.
The rebate backstop
The other half of the proposal is the one that gives it teeth. If Medicare grants the delay and the biosimilar still does not launch, CMS says a rebate could be owed. That would keep the delay from becoming a free pass when a manufacturer asks for more time but never delivers the competing product.
The practical stakes are narrow but real. The proposal sits inside the Medicare Drug Price Negotiation Program and the Medicare Prescription Drug Benefit Program, not a general drug-pricing overhaul. For beneficiaries and plans, the question is whether a biosimilar actually arrives when a company seeks more time. For manufacturers, the message is sharper: prove the launch is coming, or risk paying for the delay.